Archive for the ‘News’ Category

FDA and FTC Joint Action Aimed at Removing HCG Weight Loss Products from Market

Monday, December 12th, 2011

The FDA and FTC have issued warning letters to companies marketing over-the-counter products containing human chorionic gonadotropin (HCG) hormone that are labeled “homeopathic” remedies for weight loss.

The two agencies say the joint action is the first step in keeping these products from being marketed online and in retail outlets.

HCG is FDA-approved as a prescription drug for the treatment of some cases of female infertility and other medical conditions, but is not approved for weight loss. The letters warn the companies that they are not only in violation of federal law by selling unapproved drugs, but that they are making unsupported weight loss claims.

The labeling for the “homeopathic” HCG products states that they should be taken in conjunction with a very low calorie diet. According to the FTC, the weight loss claims are deceptive since there is no substantial scientific evidence that HCG increases weight loss beyond that resulting from the calorie-restricted diet. In addition, the FDA says that people on very low calorie diets may be at risk for a number of harmful side effects and should only use such diets under medical supervision.

According to the Warning Letters, the companies have 15 days to notify the FDA of the steps they have taken to correct the violations cited. Failure to do so may result in legal action, including seizure and injunction, or criminal prosecution.

U.S. Marshals Seize Infinity Marketing Group Products Containing Banned Ingredients

Wednesday, December 7th, 2011

U.S. Marshals at the request of the FDA have seized raw materials from Infinity Marketing Group, Inc. containing ephedrine alkaloids, ingredients banned by FDA since 2004 for use in dietary supplements.

The seized materials, more than 4,000 pounds of ephedrine alkaloid-containing raw material - Cissus quadrangularis and Cassia angustifolia extracts – were valued at $70,000.

Ephedrine alkaloids are adrenaline-like stimulants that are potentially dangerous effects to the heart. Before 2004, ephedrine alkaloids had been used extensively in dietary supplements promoted for aiding weight control and boosting sports performance and energy. However,  available data showed little evidence of ephedrine’s effectiveness. There could be a modest, short-term weight loss, but that was without any clear health benefit. Yet the alkaloid raised blood pressure and otherwise stressed the circulatory system, effects tied to heart attack, stroke and death.

Facebook Settles FTC Privacy Complaint

Monday, December 5th, 2011

Facebook has agreed to settle FTC charges that it deceived consumers by telling them they could keep their information on Facebook private, and then repeatedly allowing it to be shared and made public. The eight-count complaint charges that the claims were unfair and deceptive, and violated federal law.

Similar to the recent Google Buzz privacy settlement, the proposed Facebook settlement requires the social networking company to take specific steps to ensure it lives up to its privacy promises, including giving consumers clear and prominent notice and obtaining the user’s express consent before their information is shared beyond the privacy settings the user has established.

Facebook also will be required, for the next 20 years, to obtain independent, third-party audits certifying that it has a privacy program in place that meets or exceeds the requirements of the FTC order, as well as to ensure that the privacy of consumers’ information is protected.

The proposed settlement also

  • bars Facebook from making misrepresentations about the privacy or security of user’s personal information.
  • requires Facebook to obtain a user’s express consent before effecting changes that override their privacy preferences.
  • requires Facebook to prevent anyone from accessing a user’s material more than 30 days after the user has deleted the account.
  • requires Facebook to establish and maintain a comprehensive privacy program designed to address privacy risks associated with the development and management of new and existing products and services, and to protect the privacy and confidentiality of users’ information.
  • requires Facebook within 180 days, and every two years after that for the next 20 years, to obtain independent, third-party audits certifying that it has a privacy program in place that meets or exceeds the requirements of the FTC order, and to ensure that the privacy of consumers’ information is protected.

Among the instances cited in the complaint where allegedly made promises that it did not keep:

  • In December 2009, Facebook made changes that allowed made public certain information that users may have designated as private without warning users of the change or getting their approval in advance.
  • Facebook represented that third-party apps that users’ installed would have access only to user information that they needed to operate. In fact, the apps could access nearly all of users’ personal data – data the apps didn’t need.
  • Facebook told users they could restrict sharing of data to limited audiences – for example with “Friends Only.” In fact, selecting “Friends Only” did not prevent their information from being shared with third-party applications their friends used.
  • Facebook promised users that it would not share their personal information with advertisers when in fact, it did.

Hoodia Defendants to Turn Over Assets, Two Banned from Marketing Supplements

Tuesday, November 22nd, 2011

The FTC’s charges against three people and two companies charged with deceptive advertising of hoodia as a weight loss has resulted in a settlement where one defendant is banned from making any weight-loss claims related to foods, drugs, or dietary supplements and must turn over a vacation home and other assets to the FTC; another is banned from the dietary supplement business altogether; and all defendants are barred from making any more deceptive claims.

The FTC’s 2009 complaint alleged that the defendants made false and deceptive claims about hoodia and its effectiveness as a treatment for obesity, and falsely claimed that their ingredient was hoodia when it was not. The complaint also alleged that they falsely and deceptively claimed their product was, among other things, scientifically proven to suppress appetite, resulting in weight loss and was clinically proven to reduce caloric intake by 1,000 to 2,000 calories per day.

  • David J. Romeo, and two companies he controlled, Nutraceuticals International LLC and Stella Labs LLC, are banned from making any weight-loss claims while marketing foods, drugs, and dietary supplements. The settlement imposes a $22.5 million judgment against Romeo and the two companies, which will be suspended when Romeo forfeits his vacation home in Vermont, and assigns to the FTC the right to collect on $635,000 in business loans owed to him. If it is later determined that the financial information Romeo gave the FTC was false, the full amount of the judgment will become due.
  • Nutraceuticals International principal Craig Payton is banned from marketing any foods, drugs, or dietary supplements.
  • Nutraceuticals International marketing executive Deborah B. Vickery is required to pay a $4 million judgment, which has been suspended due to her inability to pay..
  • All five defendants are prohibited from making any false or unsupported claims about foods, drugs, or dietary supplements, and from helping others to make these claims. They also are barred from misrepresenting the results of any scientific study.

SEC Investigating Avon Bribery Allegations

Wednesday, November 2nd, 2011

The SEC is now investigating Avon in connection with allegations of bribing foreign officials that have been the subject of an internal Avon investigation disclosed in a 10-Q filing last May.

According to The Guardian, Avon’s recent regulatory filing disclosed that “a formal order of investigation” by the SEC was underway. The filing said the SEC was investigation Avon under the Foreign Corrupt Practices Act which makes it illegal U.S. firms to bribe foreign officials.

The SEC also is investigating Avon’s contacts with financial analysts in 2010 and 2011.

Government Returns $22 Million Seized in Inter-Mark Investigation

Thursday, July 14th, 2011

Federal authorities will return $22 million in funds owed to Inter-Mark member salespersons which were seized in 2010 amid accusations that Inter-Mark, an Internet-based multilevel marketing firm, actually was a Ponzi scheme.

The money will be distributed to 75,000 Inter-Mark member salespeople as commissions owed to them. According to a report in the Minneapolis Star-Tribune, some Inter-Mark members could receive as much as $200,000.

A special administrator working with Inter-Mark will verify claims and disburse the funds.

While the government would say only that they didn’t want the members deprived of their money, Inter-Mark is taking the action as an admission by the government that the company did nothing wrong.

FDA Issues Draft Guidelines for Notification of New Dietary Ingredients

Monday, July 11th, 2011

Just last week, the Food & Drug Administration issued draft guidelines for when manufacturers and distributors of dietary supplements need to notify the FDA of so called “new dietary ingredients” and to provide the agency with evidence of the safety of the ingredient.  The requirement to provide the FDA with notification of new dietary ingredients and evidence of their safety has been around since the Dietary Supplement Health and Education Act (“DSHEA”) was enacted in 1994.  However, it appears that there has been a substantial lack of compliance with this legal requirement.  According to various media reports, the FDA has received around 700 such notifications since the law went into effect in 1994.  Additionally, a law enacted just this past January (the FDA Food Safety Modernization Act) required FDA to issue the guidelines. 

Under DSHEA, a manufacturer or distributor of a dietary supplement that contains a new dietary ingredient must provide FDA with pre-market notification of the new dietary ingredient together with “information, including any citation to published articles, which is the basis on which the manufacturer or distributor has concluded that a dietary supplement containing such dietary ingredient will reasonably be expected to be safe.”  Where such notification is required, it must be given at least 75 days before the product is introduced into interstate commerce.  If this is not done, the dietary supplement will be deemed to be adulterated.

So now, you are probably asking what is a “new dietary ingredient”?  A new dietary ingredient is a dietary ingredient (a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use by man to supplement the diet by increasing total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of any of the foregoing dietary ingredients) that was not marketed in the United States in a dietary supplement before October 15, 1994.  Note that the pre-market notification described above is not required if the new dietary ingredient has been “present in the food supply as an article used for food in a form in which the food has not been chemically altered.”  In other words, the pre-market notification will not be necessary if the new dietary ingredient (a dietary ingredient that was not present in a dietary supplement in the U.S. prior to October 15, 1994) is derived from something that was in the food supply of the U.S. prior to that date and has not been chemically altered. 

Because this is all somewhat confusing, the FDA has prepared the draft guidance, which you can view here. The draft guidance answers questions in a FAQ format to assist manufacturers and distributors in determining whether they need to file the pre-market notification and evidence of safety.  It also contains templates for the preparation of a new dietary ingredient pre-market notification.  In addition, if you are so inclined, you can even comment on the draft guidance, although in order for your comments to be considered by the FDA, they must be filed within 90 days of the date that the notification was published in the Federal Register.  The notification was published on July 5, 2011—see here.

FDA hopes that with the publication of these guidelines that compliance with the pre-market notification requirements will improve.  Only time will tell.

FTC Finalizes Agreement with Oreck Settling Complaint Concerning Deceptive Health Claims

Tuesday, June 7th, 2011

The FTC has finalized the order settling charges with Vacuum cleaner and air cleaner marketer made false and unproven claims that two of its Halo vacuum and the ProShield Plus air cleaner can reduce the risk of flu and other illnesses, and eliminate virtually all common germs and allergens. As part of the settlement, Oreck agreed to pay a $750,000 fine to the FTC.

The Halo is a $599.95 upright vacuum with a light chamber that generates ultraviolet light onto the floor while vacuuming. The ProShield Plus is a $399.95 portable air cleaner that filters air particles using an electrostatic charge.

According to the FTC complaint, Oreck used infomercials, traditional TV and print ads, in-store displays and online ads to promote the products, most of which highlighted germ-killing and illness-prevention claims. The FTC charged Oreck Corporation with making these allegedly false and deceptive claims about the two products, including:

The Halo and the ProShield Plus prevent or substantially reduce the risk of flu.

The Halo and the ProShield Plus prevent or substantially reduce the risk of other illnesses or ailments caused by bacteria, viruses, molds, and allergens – such as the common cold, asthma, and allergy symptoms.

The Halo eliminates all or almost all common germs and allergens found on the floors in users’ homes, and is scientifically proven to do so.

The Halo’s ultraviolet light is effective against germs, bacteria, dust mites, mold, and viruses embedded in carpets.

The ProShield Plus eliminates all or almost all airborne particles from a typical household room under normal living conditions, and is scientifically proven to do so.

The complaint also alleges that Oreck provided deceptive advertisements to its franchised stores for their use in marketing the Halo and the ProShield Plus. By doing so, the FTC said, Oreck provided the means and instrumentalities to its distributors to deceive consumers.

Under the terms of the administrative settlement, Oreck is barred from making any of the allegedly deceptive claims in the complaint for any vacuum cleaner or any air cleaning product unless it has competent and reliable scientific evidence to support them. The company also is prohibited from making any claims about a product’s comparative health benefits without competent and reliable scientific evidence, and from misrepresenting the results of any scientific test, study, or research.

More information on the case is available in the original complaint, settlement agreement and print promotional materials exhibits.

Avon Fires Four Executives Suspected of Bribery Scheme in China Unit

Thursday, May 12th, 2011

Just over a year ago, Avon Products suspended four executives as the company investigated questionable payments to officials in various international markets. Last week, Avon disclosed in a Securities and Exchange Commission filing that it had fired four executives accused of paying bribes to Chinese government employees and was continuing to investigate possible corruptions in other countries.

The fired executives were the former general manager for China; the former head of corporate affairs for China; the former head of finance for China; and the former head of global internal audit and security, who was previously head of finance for the Asia Pacific region.

According to Avon’s May 3, 2011, 10-Q filing, the internal investigation reviewed various expenses and books and records processes, including, “travel, entertainment, gifts, use of third party vendors and consultants and related due diligence, joint ventures and acquisitions, and payments to third-party agents and others, in connection with our business dealings, directly or indirectly, with foreign governments and their employees.”

The filing said the internal investigation is continuing and could result in additional “personnel actions.” In addition, Avon said that continues to develop and enhance its U.S. Foreign Corrupt Practices Act compliance-related training, FCPA third party due diligence program and other compliance-related resources.

FDA and FTC Launch Joint Fraudulent STD Products Initiative

Monday, May 9th, 2011

In a relatively rare joint-agency action, the Federal Trade Commission and the Food and Drug Administration have launched the “Fraudulent STD Products Initiative,” to identify and remove over-the-counter products that make unproven claims to prevent, cure, and/or treat sexually transmitted diseases (STDs).

The products targeted have not been evaluated by the FDA for safety and effectiveness and may pose significant public health risk since they could delay proper medical treatment and help spread disease.

In the first step of the initiative, FDA and FTC have “co-signed” warning letters to manufacturers and others involved in the marketing of the fraudulent STD products. The letters list specific violations of FDA and FTC regulations, and the two agencies will monitor the responses and take additional action as needed to ensure enforcement. Among the products targeted are Medavir, Herpaflor, Viruxo, C-Cure, and Never An Outbreak.

The companies that received the warning letters claim that their products treat a range of STDs, including herpes, chlamydia, genital warts, HIV, and AIDS. Some of the products are marketed as dietary supplements, but since they are being sold to treat disease, the FDA considers them all drug products that fall under the jurisdiction of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and cannot be sold through interstate commerce without an FDA-approved new drug application.

On the FTC side of the initiative, FTC considers the marketing of the products a “scam” utilizing deceptive advertising practices. They are being advertised as offering health benefits that are not supported by scientific evidence and  thus violate the FTC act.